UPDATE 1-Novartis Exelon patch gets EU nod for Alzheimer's
(Adds background)
ZURICH, Sept 24 (Reuters) - The European Union has approved Novartis's (NOVN.VX) Exelon skin patch to treat Alzheimer's disease, the Swiss drugmaker said on Monday.
"The European Commission has approved Exelon patch
(rivastigmine transdermal patch), an innovative way to deliver this effective medicine to patients suffering from mild to moderately severe Alzheimer's disease," the company said.
The approval was expected after the European Medicines Agency -- whose recommendations the EU normally follows -- backed the drug in July.
The United States approved the Alzheimer patch, which is applied to the back, chest or upper arm, in July.
U.S. health officials warned Novartis in August that a promotion for Exelon made misleading claims about the medicine's effectiveness and risks.
Exelon maintains steady drug levels in the bloodstream to help fight Alzheimer's, a disease that alters the brain, causing impaired memory, thinking and behaviour.
On Friday, the European Union recommended Novartis's experimental leukaemia drug Tasigna and a new tablet called Eucreas, combining the Swiss group's Galvus pill with the older medicine metformin as a treatment for diabetes. For a company statement, click on [CNR-NOVN.VX].
((Reporting by Douwe Miedema
Editing by Quentin Bryar
Reuters Messaging:
rm://douwe.miedema.reuters.com@reuters.net
Email: zurich.newsroom@news.reuters.com
Telephone: +41 (0)44 631 7354)) Keywords: NOVARTIS EXELON/
(C) Reuters 2007. All rights reserved. Republication or redistribution ofReuters content, including by caching, framing or similar means, is expresslyprohibited without the prior written consent of Reuters. Reuters and the Reuterssphere logo are registered trademarks and trademarks of the Reuters group ofcompanies around the world.nL24278310
